Development of functional dendrisomes based on a single molecule of polyesterbenzylether dendrimer and their application in cancer stem cell therapy
Source abstract
Abstract
Abstract The differentiation therapy of breast cancer stem cells (CSCs) represents a significant strategy to treat cancer, but inefficient delivery to CSCs hinders the efficacy of differentiation agents. In this work, we report a type of functional dendrisomes constructed by the synthesized amphiphilic dendrimers, which enhance cellular uptake by breast CSCs, differentiate breast CSCs by carrying all-trans retinoic acid (ATRA), and increase the anticancer efficacy by carrying ATRA and docetaxel (DTX) in vitro and in breast cancer-bearing mice. The study further reveals the mechanism of cellular uptake by breast CSCs and uncovers the differentiation mechanism by analyzing relevant signal molecules, transcription factors, and cell cycle-associated signaling pathways during differentiation therapy in breast CSCs. Hence, this study offers a novel type of functional dendrisomes for differentiation therapy of breast CSCs and has significant clinical implications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Dendrimers and Hyperbranched Polymers · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Sreepadmanabh, M. et al. Investigations into the cancer stem cell niche using in-vitro 3-D tumor models and microfluidics. Biotechnol. Adv. 36, 1094–1110 (2018).10.1016/j.biotechadv.2018.03.009 ↗
2. Charafe-Jauffret, E. et al. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res. 73, 7290–7300 (2013).10.1158/0008-5472.CAN-12-4704 ↗
3. Yamamoto, M. et al. NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat. Commun. 4, 2299 (2013).10.1038/ncomms3299 ↗
4. Flemming, A. Cancer stem cells: targeting the root of cancer relapse. Nat. Rev. Drug Discov. 14, 165 (2015).10.1038/nrd4560 ↗
5. Dean, M. et al. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275–284 (2005).10.1038/nrc1590 ↗
6. Kinsella, T. J. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin. Cancer Res. 15, 1853–1859 (2009).10.1158/1078-0432.CCR-08-1307 ↗
7. Siegel, R. L. et al. Cancer statistics. CA Cancer J. Clin. 68, 7–30 (2018).10.3322/caac.21442 ↗
8. Pack, D. W. et al. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 4, 581–593 (2005).10.1038/nrd1775 ↗
9. Lee, C. C. et al. Designing dendrimers for biological applications. Nat. Biotechnol. 23, 1517–1526 (2005).10.1038/nbt1171 ↗
10. Markman, J. L. et al. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 65, 1866–1879 (2013).10.1016/j.addr.2013.09.019 ↗
11. Fang, J. et al. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 136–151 (2011).10.1016/j.addr.2010.04.009 ↗
12. Genchi, G. An overview on D-amino acids. Amino Acids 49, 1521–1533 (2017).10.1007/s00726-017-2459-5 ↗
13. Senior, J. & Gregoriadis, G. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci. 30, 2123–2136 (1982).10.1016/0024-3205(82)90455-6 ↗
14. Allenby, G. et al. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc. Natl Acad. Sci. USA 90, 30–34 (1993).10.1073/pnas.90.1.30 ↗
15. Tallman, M. S. et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99, 759–767 (2002).10.1182/blood.V99.3.759 ↗
16. Mirza, N. et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66, 9299–9307 (2006).10.1158/0008-5472.CAN-06-1690 ↗
17. Qi, W. X. et al. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 29, 117–125 (2013).10.1185/03007995.2012.756393 ↗
18. Wang, H. et al. Multiple mechanisms underlying aquired resistance to taxanes in selected docetaxel resistant MCF-7 breast cancer cells. BMC Cancer 14, 37 (2014).10.1186/1471-2407-14-37 ↗
19. Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91, 3–6 (2015).10.1016/j.addr.2015.01.002 ↗
20. Rothbard, J. B. et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6, 1253–1257 (2000).10.1038/81359 ↗
21. Chapman, D. & Quinn, P. J. A method for the modulation of membrane fluidity: homogeneous catalytic hydrogenation of phospholipids and phospholipids and phospholipid-water model biomembranes. Proc. Natl Acad. Sci. USA. 73, 3971–3975 (1976).10.1073/pnas.73.11.3971 ↗
22. Kastantin, M. et al. Effect of the lipid chain melting transition on the stability of DSPE-PEG (2000) micelles. Langmuir 25, 7279–7286 (2009).10.1021/la900310k ↗
23. Li, S. D. & Huang, L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta 1788, 2259–2266 (2009).10.1016/j.bbamem.2009.06.022 ↗
24. Mu, L. M. et al. Dual-functional drug liposomes in treatment of resistant cancers. Adv. Drug Deliv. Rev. 115, 46–56 (2017).10.1016/j.addr.2017.04.006 ↗
25. McMahon, H. T. & Boucrot, E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 12, 517–533 (2011).10.1038/nrm3151 ↗
26. Pastuszkac, M. K., Okamoto, C. T., Hamm-Alvarez, S. F. & MacKay, J. A. Flipping the switch on clathrin-mediated endocytosis using thermally responsive protein microdomains. Adv. Funct. Mater. 24, 5340–5347 (2014).10.1002/adfm.201400715 ↗
27. Baisa, G. A., Mayers, J. R. & Bednarek, S. Y. Curr. Opin. Budding and braking news about clathrin-mediated endocytosis. Plant Biol. 16, 718–725 (2013).
28. Nel, A. E. et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8, 543–557 (2009).10.1038/nmat2442 ↗
29. Sun, P. Z. et al. Highly selective charge-guided ion transport through a hybrid membrane consisting of anionic graphene oxide and cationic hydroxide nanosheet superlattice units. NPG Asia Mater. 8, e259 (2016).10.1038/am.2016.38 ↗
30. Li, W. Q. et al. Preoccupation of empty carriers decreases endo-/lysosome escape and reduces the protein delivery efficiency of mesoporous silica nanoparticles. ACS Appl. Mater. Interfaces 10, 5340–5347 (2018).10.1021/acsami.7b18577 ↗
31. Leid, M. et al. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem. Sci. 17, 427–433 (1992).10.1016/0968-0004(92)90014-Z ↗
32. Li, F. et al. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 17, 3–14 (2007).10.1038/sj.cr.7310118 ↗
33. Jaggupilli, A. & Elkord, E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin. Dev. Immunol. 2012, 708036 (2012).10.1155/2012/708036 ↗
34. Patrawala, L. et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 65, 6207–6219 (2005).10.1158/0008-5472.CAN-05-0592 ↗
35. Yi, T. F. et al. Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc. Natl Acad. Sci. USA. 111, 2182–2190 (2014).10.1073/pnas.1404943111 ↗
36. Osta, W. A. et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64, 5818–5824 (2004).10.1158/0008-5472.CAN-04-0754 ↗
37. Zhang, X. K. et al. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 355, 441–446 (1992).10.1038/355441a0 ↗
38. Zelent, A. et al. Translocations of the RAR alpha gene in acute promyelocytic leukemia. Oncogene 20, 7186–7203 (2001).10.1038/sj.onc.1204766 ↗
39. Casini, T. & Pelicci, P. G. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene 18, 3235–3243 (1999).10.1038/sj.onc.1202630 ↗
40. Seewaldt, V. L. et al. All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ. 8, 631–641 (1997).